{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:18:46Z","timestamp":1787811526438,"version":"build-2784847793"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with C-TIRADS 3 or 4 nodules who have undergone fine-needle aspiration cytology (FNAC), subsequent management decisions remain challenging, especially when cytological results are discordant with imaging findings or indeterminate. We built a nomogram incorporating BRAF V600E, serum biomarkers, and ultrasound features to provide an individualized risk estimate of malignancy for these nodules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively included 300 patients with C-TIRADS 3 or 4 nodules. All nodules were confirmed by postoperative pathology or cytology. Among these, 76 were malignant and 224 benign. After running LASSO regression with 10-fold cross-validation and applying the 1-standard error rule to select core predictors, we built the nomogram using Firth-penalized logistic regression. Internal validity was checked using bootstrap resampling with 1,000 iterations while the model\u2019s performance was evaluated using ROC curves, calibration (Hosmer\u2013Lemeshow test, Brier score) and decision curve analysis (DCA). The additional predictive value beyond the C-TIRADS system was measured by the Net Reclassification Index (NRI) and the Integrated Discrimination Improvement (IDI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five independent predictors were finally selected: BRAF V600E mutation (OR\u202f=\u202f36.455, 95% CI: 13.381\u2013118.094), TgAb positivity (OR\u202f=\u202f4.808, 95% CI: 2.289\u201310.486), microcalcifications (OR\u202f=\u202f4.168, 95% CI: 1.880\u20139.424), aspect ratio &amp;gt; 1 (OR\u202f=\u202f3.027, 95% CI: 1.285\u20137.115), and serum VEGF (per 100\u202fpg\/mL increase, OR\u202f=\u202f3.798, 95% CI: 1.763\u20138.677). Each predictor was independently associated with malignancy (all\n                      <jats:italic>P<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). The area under the curve (AUC) of our nomogram reached 0.890 (95% CI: 0.845\u20130.935; bootstrap-corrected: 0.886), which was significantly higher than that of C-TIRADS alone (AUC\u202f=\u202f0.746,\n                      <jats:italic>P<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Reclassification analysis yielded a categorical NRI of 0.436 (95% CI: 0.316\u20130.551,\n                      <jats:italic>P<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and an IDI of 0.263 (95% CI: 0.182\u20130.341,\n                      <jats:italic>P<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Calibration was satisfactory: the Hosmer\u2013Lemeshow\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      gave 4.61 (\n                      <jats:italic>P<\/jats:italic>\n                      \u202f=\u202f0.799), and the Brier score was 0.104. DCA demonstrated a higher net benefit across threshold probabilities ranging from 2 to 90%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The nomogram demonstrated good discriminative performance in C-TIRADS 3 or 4 nodules, supporting its utility as a post-FNAC decision aid.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1908160","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:39:45Z","timestamp":1787809185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram integrating BRAF V600E, serum biomarkers, and ultrasound features for malignancy risk stratification in C-TIRADS category 3 and 4 thyroid nodules"],"prefix":"10.3389","volume":"13","author":[{"given":"Yu","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1029926","DOI":"10.3389\/fonc.2022.1029926","article-title":"Mapping global epidemiology of thyroid nodules among general population: a systematic review and meta-analysis","volume":"12","author":"Mu","year":"2022","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"20251079","DOI":"10.1515\/biol-2025-1079","article-title":"Analysis of the detection rate and related factors of thyroid nodules in the healthy population","volume":"20","author":"Han","year":"2025","journal-title":"Open Life Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12020-020-02441-y","article-title":"2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS","volume":"70","author":"Zhou","year":"2020","journal-title":"Endocrine"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1227339","DOI":"10.3389\/fendo.2023.1227339","article-title":"Diagnostic efficiency among Eu-\/C-\/ACR-TIRADS and S-detect for thyroid nodules: a systematic review and network meta-analysis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e250113","DOI":"10.1530\/ETJ-25-0113","article-title":"Analysis of FNAC indication in thyroid nodules assessed as low risk according to various TIRADSs","volume":"14","author":"Trimboli","year":"2025","journal-title":"Eur Thyroid J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eprac.2024.05.016","article-title":"Thyroid nodules: past, present, and future","volume":"31","author":"Parsa","year":"2025","journal-title":"Endocr Pract"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/jcm12020398","article-title":"Evaluation of the performance of ACR TI-RADS also considering those nodules with no indication of FNAC: a single-center experience","volume":"12","author":"Amendola","year":"2023","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"101039","DOI":"10.1016\/j.modpat.2026.101039","article-title":"Current perspectives on thyroid nodule evaluation: integrating cytomorphology, ultrasound risk stratification, and molecular testing","author":"Pusztaszeri","year":"2026","journal-title":"Mod Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e90292","DOI":"10.7759\/cureus.90292","article-title":"A systematic review of the diagnostic role of BRAF V600E testing in thyroid nodules with atypia of undetermined significance","volume":"17","author":"Saleem","year":"2025","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ejso.2016.11.003","article-title":"BRAFV600E mutation as a predictor of thyroid malignancy in indeterminate nodules: a systematic review and meta-analysis","volume":"43","author":"Jinih","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.62347\/GARM5333","article-title":"Efficacy of color Doppler ultrasound signs combined with serum tumor-specific growth factor in the diagnosis of differentiated thyroid cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Am J Transl Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/SLA.0b013e31815fa447","article-title":"Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma","volume":"247","author":"Yu","year":"2008","journal-title":"Ann Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3892\/mco.2019.1886","article-title":"Positive thyroid antibodies and risk of thyroid cancer: a systematic review and meta-analysis","volume":"11","author":"Xiao","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: part II \u2013 binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/diagnostics15060686","article-title":"External validation of a predictive model for thyroid cancer risk with decision curve analysis","volume":"15","author":"Fern\u00e1ndez Alba","year":"2025","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e250225","DOI":"10.1530\/ETJ-25-0225","article-title":"BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity","volume":"14","author":"Riesco-Eizaguirre","year":"2025","journal-title":"Eur Thyroid J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.21037\/gs-20-430","article-title":"Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma \u2013 a contemporary systematic review","volume":"9","author":"Rashid","year":"2020","journal-title":"Gland Surg"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12020-022-03176-8","article-title":"The combination of BRAF V600E mutation and Chinese thyroid imaging reporting and data system is helpful in the management of AUS\/FLUS thyroid nodules","volume":"78","author":"Li","year":"2022","journal-title":"Endocrine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"15626","DOI":"10.3390\/ijms232415626","article-title":"Association of BRAFV600E mutation with the aggressive behavior of papillary thyroid microcarcinoma: a meta-analysis of 33 studies","volume":"23","author":"Attia","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1551271","DOI":"10.3389\/fendo.2025.1551271","article-title":"Mechanisms underlying the promotion of papillary thyroid carcinoma occurrence and progression by Hashimoto\u2019s thyroiditis","volume":"16","author":"Xue","year":"2025","journal-title":"Front Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/endrev\/bnaf035","article-title":"DNA damage and repair in thyroid physiology and disease","volume":"47","author":"Arczewska","year":"2026","journal-title":"Endocr Rev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1349041","DOI":"10.3389\/fendo.2024.1349041","article-title":"The relationship between thyroid peroxidase antibody and differentiated thyroid cancer: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000371741","article-title":"Iodine, thyroid autoimmunity and cancer","volume":"4","author":"Fiore","year":"2015","journal-title":"Eur Thyroid J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12957-024-03501-7","article-title":"Association of thyroid autoantibodies with aggressive characteristics of papillary thyroid cancer: a case-control study","volume":"22","author":"Tan","year":"2024","journal-title":"World J Surg Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1210\/clinem\/dgad408","article-title":"Elevated preoperative TPO ab titers decrease risk for DTC in a linear fashion: a retrospective analysis of 1635 cases","volume":"109","author":"Paparodis","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.2147\/IJGM.S473731","article-title":"Histopathological analysis of thyroid nodules with taller-than-wide shape in adults","volume":"17","author":"Yang","year":"2024","journal-title":"Int J Gen Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"7718","DOI":"10.3390\/ijms21207718","article-title":"Molecular aspects of thyroid calcification","volume":"21","author":"Ferreira","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00428-024-03934-1","article-title":"Psammoma bodies in thyroid: are they always indicative of malignancy? A multi-institutional study","volume":"485","author":"Rossi","year":"2024","journal-title":"Virchows Arch"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.21873\/invivo.12014","article-title":"Taller-than-wide thyroid nodules with microcalcifications are at high risk of malignancy","volume":"34","author":"Papapostolou","year":"2020","journal-title":"In Vivo"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.3390\/medicina61122217","article-title":"Microcalcification and irregular margins as key predictors of thyroid cancer: integrated analysis of EU-TIRADS, Bethesda, and histopathology","volume":"61","author":"\u00c7imen","year":"2025","journal-title":"Medicina"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00432-024-05714-5","article-title":"Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors","volume":"150","author":"Kang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/biomedicines14051126","article-title":"Current studies on the hypoxic tumor microenvironment in thyroid cancer: from molecular mechanisms to clinical therapeutic perspectives","volume":"14","author":"Peng","year":"2026","journal-title":"Biomedicine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1530\/EJE-10-0967","article-title":"VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma","volume":"164","author":"Karaca","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1210\/jc.2005-2836","article-title":"Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer","volume":"91","author":"Jo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"101854","DOI":"10.1016\/j.tranon.2023.101854","article-title":"CXCL16 promotes tumor metastasis by regulating angiogenesis in the tumor micro-environment of BRAF V600E mutant colorectal cancer","volume":"41","author":"Deng","year":"2024","journal-title":"Transl Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.canlet.2015.07.012","article-title":"Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E)","volume":"380","author":"Husain","year":"2016","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1908160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:39:46Z","timestamp":1787809186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1908160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1908160"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1908160","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1908160"}}